Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Stopped Unable to identify patients who meet eligibility requirements of tissue needed for analysis.

Conditions

• NSCLC, Stage III

Interventions

• DIAGNOSTIC_TEST: Signatera ctDNA test
• DRUG: Durvalumab

Sponsor

Indiana University